Compare Dell Technologies Inc (DELL) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Dell Technologies (DELL) trades at $574.74, down 0.73% on the day, with a bullish technical signal and strong fundamental momentum. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $7.04 surpassing expectations by 43%. The company's AI server business is a key growth driver, with a backlog surging to $95 billion and fiscal 2027 revenue guidance raised to approximately $192 billion. Positive analyst sentiment is reflected in a 55.56% buy rating, though the stock trades above the consensus price target of $566.35.

The outlook for Dell is optimistic, driven by explosive AI server demand and robust financial performance. Investment opportunities include continued revenue growth and margin expansion, supported by a capital-light model. Risks include execution challenges in meeting high demand, competitive pressures, and market volatility. The stock's current valuation at a P/E of 33.42 may limit near-term upside if growth moderates.

INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.

Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.